Baidu
map

Diabetic Med:重新评估体重指数的重要性

2017-08-31 MedSci MedSci原创

近日,国际杂志 《Diabetic Medicine》上在线发表一项关于成人身高和葡萄糖耐量进而重新评估体重指数的重要性的研究。

近日,国际杂志 《Diabetic Medicine》上在线发表一项关于成人身高和葡萄糖耐量进而重新评估体重指数的重要性的研究。

研究人员基于75g口服葡萄糖耐量试验的结果,研究成人身高和葡萄糖调节之间的关系,以及身高和肥胖对葡萄糖值的综合影响。

针对芬兰西南部的有高危心血管危险健康人群中,研究人员进行了以人口为基础的横断面研究。该研究包括265945-70岁的参与者,他们至少有一个心血管危险因素,但以前没有诊断糖尿病或显示出心血管疾病。在所有参与者中进行口服葡萄糖耐量试验。测量体重和体重,计算BMI。参与者根据正态分布分为五个高度组。为进一步分析高度与葡萄糖浓度的关系,参与者分为四个BMI组(<25.0kg/m225-29.9kg/ m230-34.9 kg/m2;≥35kg/m2)。

研究发现身高与2小时血浆葡萄糖呈负相关,但与空腹血浆葡萄糖浓度无关,且没有观察到性别差异。2小时血浆葡萄糖值随着BMI的增加而增加,因此三个最低BMI组的身高与2小时血浆葡萄糖呈负相关,但最高BMI组(P=0.33)无这种关系。

研究表明,与较矮的人群BMI高达35kg/m2的相比,较高的人群具有较低2小时血浆葡萄糖浓度。需要校正身高和BMI,以准确解释口服葡萄糖耐量试验。

原始出处:

S. K. J. Rehunen, H. Kautiainen, J. G. Eriksson et al. Adult height and glucose tolerance: a re-appraisal of the importance of body mass index

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1760195, encodeId=e9461e60195a8, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Nov 12 03:33:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638024, encodeId=68b6163802425, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Oct 15 00:33:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942444, encodeId=567119424446b, content=<a href='/topic/show?id=851b960646e' target=_blank style='color:#2F92EE;'>#重要性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96064, encryptionId=851b960646e, topicName=重要性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Feb 27 11:33:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970525, encodeId=46d619e052508, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Mar 02 17:33:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607998, encodeId=a475160e99885, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 13:33:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1760195, encodeId=e9461e60195a8, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Nov 12 03:33:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638024, encodeId=68b6163802425, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Oct 15 00:33:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942444, encodeId=567119424446b, content=<a href='/topic/show?id=851b960646e' target=_blank style='color:#2F92EE;'>#重要性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96064, encryptionId=851b960646e, topicName=重要性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Feb 27 11:33:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970525, encodeId=46d619e052508, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Mar 02 17:33:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607998, encodeId=a475160e99885, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 13:33:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1760195, encodeId=e9461e60195a8, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Nov 12 03:33:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638024, encodeId=68b6163802425, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Oct 15 00:33:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942444, encodeId=567119424446b, content=<a href='/topic/show?id=851b960646e' target=_blank style='color:#2F92EE;'>#重要性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96064, encryptionId=851b960646e, topicName=重要性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Feb 27 11:33:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970525, encodeId=46d619e052508, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Mar 02 17:33:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607998, encodeId=a475160e99885, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 13:33:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]
    2018-02-27 mgqwxj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1760195, encodeId=e9461e60195a8, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Nov 12 03:33:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638024, encodeId=68b6163802425, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Oct 15 00:33:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942444, encodeId=567119424446b, content=<a href='/topic/show?id=851b960646e' target=_blank style='color:#2F92EE;'>#重要性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96064, encryptionId=851b960646e, topicName=重要性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Feb 27 11:33:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970525, encodeId=46d619e052508, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Mar 02 17:33:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607998, encodeId=a475160e99885, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 13:33:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1760195, encodeId=e9461e60195a8, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Nov 12 03:33:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638024, encodeId=68b6163802425, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Oct 15 00:33:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942444, encodeId=567119424446b, content=<a href='/topic/show?id=851b960646e' target=_blank style='color:#2F92EE;'>#重要性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96064, encryptionId=851b960646e, topicName=重要性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Feb 27 11:33:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970525, encodeId=46d619e052508, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Mar 02 17:33:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607998, encodeId=a475160e99885, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 13:33:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]

相关资讯

NEJM:利拉鲁肽可显著降低糖尿病肾病风险

研究表明,对于II糖尿病患者,服用利拉鲁肽可显著降低患者糖尿病肾病的发生和疾病进展

中国在全球率先开展干细胞教育治疗青少年发病1型糖尿病

8月30日下午,在中南大学湘雅二医院代谢内分泌科三病区病房里,来自美国纽约的1型糖尿病患儿Ivan正在接受干细胞教育治疗。作为全球首批接受该方法治疗的青少年发病1型糖尿病患者,经过前两个疗程的治疗后,Ivan病情明显好转。

Diabetic Med:预先存在的糖尿病是肾移植后细胞排斥反应率升高的危险因素?

近日,国际杂志 《Diabetic Medicine》上在线发表一项关于预先存在的糖尿病是肾移植后细胞排斥反应率升高的危险因素的观察性队列研究。在一个很好的临床队列中,在现代免疫抑制的背景下,为了研究糖尿病患者是否有较高的肾移植排斥的风险。

Diabetic Med:黑人,南亚和欧洲白人少数民族的握力和糖尿病患病率之间的关系

近日,国际杂志 《Diabetic Medicine》上在线发表一项关于英国Biobank研究对418 656名参与者的横断面分析研究,探讨黑人,南亚和欧洲白人少数民族的握力和糖尿病患病率之间的关系。

Mol Ther:二苯并氮杂草衍生物有望成为糖尿病新希望!

普渡大学的研究人员进行的一项研究表明,褐变的特殊脂肪可以系统性的改善新陈代谢,dibenzazepine纳米颗粒的潜在作用。

Diabetic Med:对提供糖尿病教育和支持的卫生保健专业人员培训不足

近日,国际杂志 《Diabetic Medicine》上在线发表一项关于糖尿病态度,愿望和需求(DAWN2)研究结果,指出了对提供糖尿病教育和支持的卫生保健专业人员培训不足。使用糖尿病态度,愿望和需求(DAWN2)研究的数据,研究为卫生保健专业人员提供糖尿病自我管理教育和培训的全球规范。研究人员共调查了17个国家的4785名护理糖尿病患者的卫生保健专业人员,以评估糖尿病保健服务,自我管理支持和培训

Baidu
map
Baidu
map
Baidu
map